ProQR Therapeutics N.V. — FY2018 Form 20-F
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide separate Q4 financial results. Financial statements are audited and prepared under IFRS as issued by the IASB, with amounts below in euros unless noted.
Business context and financial performance
ProQR is a clinical-stage biotechnology company developing RNA-based medicines for rare genetic diseases. It had no approved products and generated no product or royalty revenue; reported other income primarily reflects grants and related funding. It reported continuing losses and expects significant R&D spending.
| Metric (€ in thousands, except per-share data) | FY2018 | FY2017 | Change |
|---|---|---|---|
| Other income | 5,761 | 1,495 | Up 285% |
| Research and development costs | 29,514 | 31,153 | Down 5% |
| General and administrative costs | 12,540 | 10,840 | Up 16% |
| Operating loss | (36,293) | (40,498) | Loss narrowed |
| Net loss | (37,086) | (43,675) | Loss narrowed 15% |
| Basic and diluted loss per share | €(1.08) | €(1.72) | Improved |
| Operating cash flow | (28,493) | (34,951) | Cash use declined |
| Cash and cash equivalents, year-end | 105,580 | 48,099 | Up 119% |
| Total assets, year-end | 110,231 | 53,103 | Up 108% |
| Total liabilities, year-end | 17,546 | 13,778 | Up 27% |
| Total equity, year-end | 92,685 | 39,325 | Up 136% |
Margins based on product revenue are not meaningful because the company had no product sales. No standalone gross margin is reported. Financing cash flow was €86.457 million, largely reflecting €84.191 million of net proceeds from the September share offering. Investing cash outflow was €0.312 million. Year-end borrowings were €9.386 million, reported as non-current; the filing describes fixed-rate loans and government innovation credit. The company reported no off-balance-sheet arrangements.
Material changes and business developments
- Cash increased substantially following a September 2018 offering of 6,612,500 shares at $15.75 per share, generating €89.983 million gross and €84.191 million net proceeds.
- R&D expense declined modestly year over year as eluforsen trials had been completed, while sepofarsen clinical work continued. G&A rose, including costs related to offerings, legal and consulting support, office operations, and internal controls.
- Other income rose to €5.761 million, including grant income from the final Horizon 2020 payment and funding agreements for QR-421a and QR-313.
- The October 2018 Ionis license added QR-1123 to the pipeline. ProQR issued Ionis 112,473 shares valued at $2.5 million and agreed to further milestone payments and royalties.
- QR-313’s ongoing Phase 1/2 study remained blinded; after a portfolio review, ProQR transferred conduct and completion of the program to Wings Therapeutics. A strategic spinout was announced in March 2019.
Outlook, risks, and unusual items
- Management estimated available cash would fund planned operations into 2021. This is based on its current operating plan and could change with clinical progress, costs, or financing needs. Management expected R&D expense to remain around current levels, with potential period-to-period fluctuations, and G&A to remain fairly stable.
- Planned development included a proposed Phase 2/3 sepofarsen trial in the first half of 2019, QR-421a clinical development and QR-1123 advancement toward a Phase 1/2 trial in 2019, and QR-411 clinical study planning for 2020. These are forward-looking plans, not assured outcomes.
- Sepofarsen interim Phase 1/2 findings reported improvement across vision-related measures in a small, open-label study; the filing cautions results may not be replicated. Longer-duration safety follow-up identified mild cystoid macular edema and lens opacities considered likely related to treatment; some lens-opacity cases required corrective lens replacement. No participants had discontinued at the reported cutoff.
- The company expects ongoing losses and may need additional financing. Key risks include clinical failure or delay, regulatory uncertainty, reliance on third-party manufacturers and research organizations, competition, intellectual-property disputes, and uncertainty around future product pricing and reimbursement.
- Potential contingent payments include up to approximately $16 million to CFFT following first commercial sale of eluforsen, up to $37.5 million to FFB following first commercial sale of QR-421a, and QR-1123 milestone and royalty obligations to Ionis. These obligations are conditional and would be triggered by specified events.
- A Dutch government innovation credit related to the CF program received a conditional waiver; the total loan including interest may be waived after three years if specified conditions are met. The QR-110 innovation credit provides up to €4.7 million, with repayment dependent on market approval.
- IFRS 16, effective in 2019, was expected to add approximately €2.3 million to the balance sheet and reclassify about €1.2 million of lease cash payments from operating to financing activities.
- Auditors issued an unqualified opinion on the IFRS financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal controls because of the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Confirm the cash runway against current cash burn, planned trial costs, and any subsequent financing or changes to development plans.
- Track controlled-trial outcomes and safety data for sepofarsen and QR-421a, and progress toward clinical initiation for QR-1123.
- Review the terms and potential dilution from the shelf registration and ATM facility, which authorized up to $300 million of securities in total, including up to $75 million through the ATM.
- Reconcile share counts: the cover reports 38,872,936 shares outstanding at year-end, while the financial statements report 43,149,987 issued shares, including 4,277,051 treasury shares held by the employee-option foundation.
- Check the cash-flow disclosure: the summary table reports 2018 financing cash flow of €86.457 million, while one narrative passage says €86.547 million; the detailed cash-flow statement shows €86.457 million.
- Assess contingent funding and collaboration economics, including CFFT, FFB, EBRP/EBMRF, and Ionis obligations, and confirm how future milestone payments may be funded.